MicroPort Reports 2023 Loss Within $580M; Sandoz’s Denosumab-bddz Becomes First FDA-Approved Biosimilar to Prolia/Xgeva
Proviva Therapeutics
Developer of Next-Generation Cytokine Anti-Tumor Immunotherapy
Minimally Invasive System Announces 2023 Earnings Report.
On March 5, MicroPort Medical announced that it expects revenue growth to exceed 15% in 2023, with a loss not exceeding $580 million. In 2022, the company's loss was $588 million.
On the same day, MicroPort Robot announced that it expects its revenue growth to exceed 350% in 2023, with a loss not exceeding 1.05 billion yuan.
The market for biosimilars continues to open up.
On March 5, Sandoz announced that its denosumab biosimilar, denosumab-bddz, received FDA approval for marketing. The company stated that this product is the first denosumab biosimilar approved by the FDA.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you through them.
/ 01 /
Capital Information
1) Minimally Invasive Medical Technology Reports Loss of No More Than $580 Million in 2023
On March 5, MicroPort Medical released its 2023 earnings快报. During the reporting period, the company expects revenue growth to exceed 15%, with a loss not exceeding 5.8 billion US dollars. In 2022, the company's loss was 5.88 billion US dollars.
2) Minimally Invasive Robot's Loss in 2023 Not Exceeding 1.05 Billion Yuan
On March 5, MicroPort Robot announced its 2023 earnings report. During the reporting period, the company expects revenue growth to exceed 350%, with a loss not exceeding 1.05 billion yuan.
3) Proviva Therapeutics Completes $18 Million Series A Financing
On March 5, Proviva Therapeutics announced the completion of a $18 million Series A financing round. The company stated that this funding will be used to advance the clinical development of Proviva Therapeutics' core product, PTX-912.
/ 02 /
Pharmaceuticals and Medical Devices Updates
1) Jisheng Aoma Bio IAMA-001 Nasal Spray Approved for Clinical Trials
On March 6, according to the CDE official website, Ji Sheng Ao Ma Bio's IAMA-001 Nasal Spray was approved for clinical trials to treat adult seasonal allergic rhinitis.
2) Zhongwang Medical's LPC-008 Oral Soluble Film Approved for Clinical Trials
On March 6, according to the CDE official website, Zhongwang Medical's LPC-008 oral soluble film was approved for clinical trials, intended for the treatment of signs and symptoms of idiopathic Parkinson's disease in adults.
3) Grand Pharmaceutical GPN00884 Eye Drops Approved for Clinical Trials
On March 6, according to the CDE official website, GPN00884 eye drops developed by Grand Pharmaceutical were approved for clinical trials, aiming to conduct research on delaying the progression of myopia in children.
4) Kerpharm Lidocaine Prilocaine Aerosol Approved for Clinical Use
On March 6, according to the CDE official website, Proviva Therapeutics' lidocaine and prilocaine aerosol has been approved for clinical trials, intended to treat primary premature ejaculation in adult men.
5) Janssen's Guselkumab Granted Priority Review
On March 6, according to the CDE website, Johnson & Johnson's Guselkumab is proposed for priority review, with the indication for treating adult patients with moderate to severe active Crohn's disease.
6）Henlius' Trastuzumab Approved in the Philippines and Thailand
On March 6, Henlius announced that Trastuzumab was approved in the Philippines and Thailand. The company stated that this signifies an ongoing acceleration in the expansion of the Southeast Asian market.
/ 03 /
Global Pharma News
1) Toyota Invests in Early Screening Company Craif
On March 5, Craif, a startup developing urine testing kits, announced that it had received investments from Toyoda Gosei and Toyota Boshoku, both part of the Toyota Group. The funds raised will be used for the research and development of testing services, strengthening clinical research, and recruiting human resources as the organization scales.
2) FDA Approves First Denosumab Biosimilar
On March 5, Sandoz announced that its denosumab biosimilar, denosumab-bddz, received FDA approval for marketing. The company stated that this product is the first denosumab biosimilar approved by the FDA.
3) Successful Phase 3 Clinical Trial of Semaglutide FLOW
On March 5, Novo Nordisk announced the primary results of the FLOW Phase 3 clinical trial for semaglutide. The analysis showed that 1.0 mg semaglutide reduced the risk of kidney-related events by 24% in patients with type 2 diabetes and chronic kidney disease (CKD).
4) Empros Pharma Announces Positive Results from Phase 2b Clinical Trial of Oral Weight Loss Drug
On March 5, Empros Pharma announced positive topline results from the Phase 2b clinical trial of the orlistat/acarbose combination formula EMP16. The trial results showed that this oral combination therapy reduced participants' average body weight by 8%.
Text / Zheng Xiao
PS: Welcome to scan the QR code below to add the WeChat ID of Amino Jun for communication.
